Updated:
Healthspan Capital
Healthspan Capital is a venture capital firm with a mission to invest in and support longevity biotechnology (LongBio) companies developing therapeutics to...
Healthspan Capital
Healthspan Capital is a venture capital firm with a mission to invest in and support longevity biotechnology (LongBio) companies developing therapeutics to extend healthy human lifespan. It invests in early-stage longevity biotech and regenerative medicine startups. The firm believes rejuvenation biotechnology is the future of medicine and operates a rolling fund on AngelList.
General information
Firm type
Venture Capital
Year founded
2021
Location
Region
North America
Country
United States
City
El Cerrito
Corporate office
El Cerrito, CA, United States
Principals
Nathan Cheng
General Partner
Sebastian Brunemeier
General Partner
Michael Chinen
General Partner
Prof. Matt Kaeberlein
Advisor
Prof. Claes Wahlestedt
Advisor
Josef Christensen
Advisor
Vera Gorbunova
Advisor
Dan Catron
Advisor
Michael J. Parnham
Advisor
Jack Scannell
Advisor
Boyang Wang
Senior Venture Fellow
Paolo Binetti
Venture Fellow
Alexander Tchernev
Venture Fellow
Colin Maraganore
Venture Fellow
Ryan Spangler
Venture Fellow
Nelly Weiser
Venture Fellow
Sector focus
Frequently asked questions
What does Healthspan Capital invest in?
Healthspan Capital invests in early-stage companies developing therapies, diagnostics, and digital health tools that target the biology of aging. Its mandate covers drug discovery platforms aimed at cellular senescence and epigenetic reprogramming, as well as consumer and clinical tools for measuring biological age. The firm focuses on seed and start-up rounds where foundational aging science is being translated for the first time.
What stages does Healthspan Capital target?
Healthspan Capital deploys at the earliest stages of company formation — seed and start-up — where geroscience discoveries exit academic labs and require initial venture backing. This includes pre-revenue biotech platforms, proof-of-concept diagnostics, and digital health tools that measure hallmarks of aging. The firm does not publicly list later-stage growth equity or public-market mandates.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: